

---

## MEDIA RELEASE

---

### **Ypsomed expands headquarters in Burgdorf**

**Burgdorf, 29.08.2019, 7.00 Uhr – Ypsomed opens its new and renovated buildings at the headquarters in Burgdorf. With this expansion, Ypsomed secures the additional capacities and workplaces it needs to continue growing in the future.**

Following the expansion of the insulin pen production in Solothurn in April of this year and the opening of the ultra-modern production plant for injection and infusion systems in Schwerin in north-eastern Germany last week, the new and renovated buildings at Ypsomed's headquarters in Burgdorf will be officially opened today. The expansion ensures that Ypsomed has sufficient capacities and jobs for future growth at its headquarters.

#### **Modernisation and expansion**

The tool shop, in which the injection moulding tools are manufactured and validated, has been modernised and extended. The laboratory, in which the products are tested, especially during the development phase, has also been renovated and expanded. Besides the extended tool shop and the expanded laboratory, an additional 100 office workplaces and rooms for training courses and creative workshops have been created. Furthermore, a glass porch and a terrace have been added to the canteen. Complimentary charging stations for electric cars are also available to employees.

#### **Clear commitment to Burgdorf**

In April of this year, Ypsomed announced the relocation of 110 existing workplaces from Burgdorf to Solothurn in order to create free capacities in Burgdorf. "According to our current plans, our headquarters will again employ around 600 people by the end of 2020," explained Simon Michel, CEO of Ypsomed, and confirms the company's long-standing commitment to Burgdorf, where the company's roots lie.

For further information, please contact Thomas Kutt, Head of Investor Relations at Ypsomed Holding AG, at the telephone number +41 34 424 35 55 or by e-mail ([thomas.kutt@ypsomed.com](mailto:thomas.kutt@ypsomed.com)).

**About the Ypsomed Group**

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1 700 employees. Additional information is available under [www.ypsomed.com](http://www.ypsomed.com).